Seoul, South Korea, May 6, 2021 / PRNewswire / – Nexturn Bio Inc., a subsidiary of Nexturn Bioscience Co., Ltd. (KOSDAQ: 89140) said it has secured a 50% stake in RosVivo Therapeutics Inc., a new US drug developer, as a first investment target. RosVivo recently developed RSVI-301, a new drug pipeline that uses miRNA (microRNA), which is expected to be the next generation drug after mRNA (messenger RNA), which has attracted attention as a Covid-19 vaccine. Unlike rare diseases or cancer, tackling the chronic disease “diabetes” appears to have had a positive impact on Nexturn Bio’s investment.
